Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25277814 | 0.79 | APLNR (0.34) | SMN1; SMN2GAAAPLNR | |
| SCHEMBL13818120 | 0.78 | APLNR (0.32) | APLNR | |
| SCHEMBL14880623 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL449125 | 0.76 | CHRNB2 (0.42) | SMN1; SMN2GAA | |
| SCHEMBL20167817 | 0.76 | — | — | |
| SCHEMBL31415916 | 0.73 | HDAC8 (0.41) | — | |
| SCHEMBL25934283 | 0.73 | ALDH1A1 (0.30) | — | |
| SCHEMBL24693063 | 0.73 | — | — | |
| SCHEMBL27932857 | 0.73 | CHRNB2 (0.39) | — | |
| SCHEMBL4206610 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405343-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-112236415-B | Process for the preparation of aminopyrimidines and intermediates therefor | 赛特凯恩蒂克公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023046698-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-30 | — | — | WO | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | CYTOKINETICS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | CYTOKINETICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| CN-112236415-A | Process for preparing aminopyrimidines and intermediates thereof | 赛特凯恩蒂克公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-3732166-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | Cytokinetics, Incorporated (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061786-A1 | PROCESS FOR THE PREPARATION OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF | TYMP, UMPS, DPYD | SMN1; SMN2 3123/4885GAA 2368/4885APLNR 2399/4885 |
| US-11142516-B2 | Process for the preparation of an amino-pyrimidine and intermediates thereof | TYMP, UMPS, DPYD | SMN1; SMN2 3123/4885GAA 2368/4885APLNR 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.